Clinical Trial: HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07575308) titled 'HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB' on May 04.

Brief Summary: The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB

Study Start Date: May 05

Study Type: INTERVENTIONAL

Condition: Von Willebrand Disease (VWD) Heavy Menstrual Bleeding (HMB)

Intervention: DRUG: ALN-6400

ALN-6400 will be administered subcutaneously (SC).

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Alnylam Pharmaceuticals

Disclaimer: Curated by HT Syndication....